{"product_id":"european-association-of-dermato-oncology-14th-european-post-chicago-melanoma-skin-cancer-meeting-2024","title":"European Association of Dermato-Oncology 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024","description":"\u003cdiv aria-labelledby=\"tab-title-description\" class=\"woocommerce-Tabs-panel woocommerce-Tabs-panel--description panel entry-content active\" id=\"tab-description\" role=\"tabpanel\"\u003e\n\u003cdiv class=\"prod-edition\"\u003e\n\u003cdiv class=\"field field--name-field-heading field--type-heading field--label-hidden field__item\"\u003e\n\u003ch3\u003eEuropean Association of Dermato-Oncology 14th European Post-Chicago Melanoma Skin Cancer Meeting 2024\u003c\/h3\u003e\n\u003cstrong\u003eInclude: 26 videos + 1 pdf, size: 21.1 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Target Audience: dermatologists, oncologists, pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cbr\u003e\u003cbr\u003eThe \u003cstrong\u003e14th European Post-Chicago Melanoma Skin Cancer Meeting 2024\u003c\/strong\u003e is an interdisciplinary global conference focused on the latest advancements in \u003cstrong\u003emelanoma and skin cancer\u003c\/strong\u003e. It will take place on \u003cstrong\u003eJune 27–28, 2024\u003c\/strong\u003e, at the \u003cstrong\u003eHilton Hotel Munich Park, Germany\u003c\/strong\u003e.\u003cbr\u003e\u003ch3 class=\"text-base-strong sm:text-md-strong pb-1 [\u0026amp;:not(:first-child)]:pt-3.5\"\u003eKey Details:\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat\u003c\/strong\u003e: Hybrid (In-person \u0026amp; Virtual)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCongress Presidents\u003c\/strong\u003e: Axel Hauschild (Kiel, Germany) \u0026amp; Claus Garbe (Tuebingen, Germany)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTopics Covered\u003c\/strong\u003e:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eResults and interpretations of \u003cstrong\u003eASCO 2024 presentations\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdverse event management\u003c\/strong\u003e for targeted and immunotherapies\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGut microbiome\u003c\/strong\u003e and its role in immuno-oncology\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBispecific T-cell engagers (BTE)\u003c\/strong\u003e in cutaneous and uveal melanomas\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNeoadjuvant vs. perioperative immune checkpoint inhibitors (ICI)\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCutaneous T-cell lymphoma (CTCL)\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAdjuvant treatment of melanoma\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInteractive case discussions\u003c\/strong\u003e on complex melanoma and non-melanoma cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThis meeting provides a \u003cstrong\u003ecomprehensive overview\u003c\/strong\u003e of new developments in \u003cstrong\u003emelanoma diagnostics, drug development, and clinical trials\u003c\/strong\u003e, fostering interaction between \u003cstrong\u003eclinicians, researchers, and industry experts\u003c\/strong\u003e\n\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cbr\u003eThe \u003cstrong\u003e14th European Post-Chicago Melanoma Skin Cancer Meeting 2024\u003c\/strong\u003e is designed for medical professionals specializing in \u003cstrong\u003emelanoma and skin cancer treatment\u003c\/strong\u003e. The target audience includes:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDermatologists\u003c\/strong\u003e and \u003cstrong\u003eoncologists\u003c\/strong\u003e focused on melanoma and skin cancer.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eClinical researchers\u003c\/strong\u003e involved in melanoma diagnostics and therapy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePathologists\u003c\/strong\u003e specializing in skin cancer histopathology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMedical professionals\u003c\/strong\u003e interested in immuno-oncology and targeted therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIndustry experts\u003c\/strong\u003e working on drug development and clinical trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThis interdisciplinary conference provides a \u003cstrong\u003ecomprehensive overview\u003c\/strong\u003e of the latest advancements in \u003cstrong\u003emelanoma diagnostics, treatment strategies, and emerging therapies\u003c\/strong\u003e. It fosters direct communication between \u003cstrong\u003eclinicians, researchers, and industry representatives\u003c\/strong\u003e\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e16_EPCM-2024_FINAL-Program_web.pdf\u003cbr\u003eCLOSING REMARKS.mp4\u003cbr\u003eKEYNOTE LECTURE I.mp4\u003cbr\u003eKEYNOTE LECTURE II.mp4\u003cbr\u003eKEYNOTE LECTURE III.mp4\u003cbr\u003eKEYNOTE LECTURE IV.mp4\u003cbr\u003eOPENING OF THE CONFERENCE.mp4\u003cbr\u003ePARALLEL SYMPOSIUM I Adverse event management of targeted and immunotherapies.mp4\u003cbr\u003ePARALLEL SYMPOSIUM II Real world evidence studies from registries.mp4\u003cbr\u003ePARALLEL SYMPOSIUM III Cutaneous T-cell lymphoma (CTCL).mp4\u003cbr\u003ePARALLEL SYMPOSIUM IV Interactive Discussion of complex melanoma cases.mp4\u003cbr\u003ePARALLEL SYMPOSIUM V Interactive Discussion of complex non-melanoma cases.mp4\u003cbr\u003ePARALLEL SYMPOSIUM VI Innovative therapies for orphan diseases.mp4\u003cbr\u003eSATELLITE SYMPOSIUM I NOVARTIS Gold Sponsor Yesterday, Today \u0026amp; Tomorrow Long-Term Benefits with Targeted Therapy in Adjuvant Melanoma.mp4\u003cbr\u003eSATELLITE SYMPOSIUM II BMS Gold Sponsor IO-Combinations in Melanoma- How to Proceed – Less or More.mp4\u003cbr\u003eSATELLITE SYMPOSIUM III MSD Platinum Sponsor Advancements in Early Melanoma Integrating Recent Updates into Clinical Practice.mp4\u003cbr\u003eSATELLITE SYMPOSIUM V REGENERON Platinum Sponsor Evolving Perspectives on Treatment Roadmap for Advanced Non-melanoma Skin Cancer.mp4\u003cbr\u003eSATELLITE SYMPOSIUM VI PHILOGEN Sponsor Novel treatments for locally advanced skin cancers.mp4\u003cbr\u003eSATELLITE SYMPOSIUM VII MERCK Bronze Sponsor Leveraging Real-World Evidence in Advanced Merkel Cell Carcinoma- Insights from Clinical Practice.mp4\u003cbr\u003eSYMPOSIUM I My personal highlights at ASCO 2024.mp4\u003cbr\u003eSYMPOSIUM II Which vaccines work and which not.mp4\u003cbr\u003eSYMPOSIUM III The role of gut microbiome for immunooncology.mp4\u003cbr\u003eSYMPOSIUM IV Bispecific T-cell engagers (BTE) in cutaneous and uveal melanomas (unrestricted Educational Grant Immunocore).mp4\u003cbr\u003eSYMPOSIUM V Controversy- Is neoadjuvant or perioperative ICI already standard of care.mp4\u003cbr\u003eSYMPOSIUM VI Adjuvant treatment of melanoma.mp4\u003cbr\u003eSYMPOSIUM VII Intralesional therapies for melanoma and NMSC.mp4\u003cbr\u003eSYMPOSIUM VIII What’s new in NMSC Publication highlights from the last 12 months.mp4\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954482614370,"sku":"MED-AMB04233","price":60.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/European-Association-of-Dermato-Oncology-14th-European-Post-Chicago-Melanoma-Skin-Cancer-Meeting-2024-1-1.jpg?v=1779377626","url":"https:\/\/meducourse.com\/products\/european-association-of-dermato-oncology-14th-european-post-chicago-melanoma-skin-cancer-meeting-2024","provider":"Meducourse","version":"1.0","type":"link"}